Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 15/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.58 |
| ▸ | PIM1 | P11309 | 6/20 | 0.58 |
| ▸ | GSK3B | P49841 | 6/20 | 0.58 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2213348 | 0.92 | PIK3CD (0.56) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| SCHEMBL1960291 | 0.90 | PIK3CD (0.56) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| SCHEMBL2215849 | 0.88 | PIK3CD (0.61) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| SCHEMBL458971 | 0.88 | PIK3CD (0.61) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| SCHEMBL4395028 | 0.88 | PIK3CD (0.61) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| SCHEMBL13570073 | 0.88 | PIK3CD (0.61) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| SCHEMBL2210311 | 0.88 | PIK3CD (0.62) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| SCHEMBL2214792 | 0.88 | PIM1 (0.42) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| SCHEMBL1433362 | 0.88 | PIM1 (0.42) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| SCHEMBL2213473 | 0.87 | PIK3CD (0.55) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | claimed |
| EP-2300437-B1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LTD (GB) | 2013-11-20 | — | — | EP | claimed |
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | US | claimed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| EP-2300437-B1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LTD (GB) | 2013-11-20 | — | — | EP | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | PIK3CA, PIK3CD, PI4KA | PIK3CD 2/4885PIK3CB 6/4885PIK3CG 15/4885 |
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | PIK3CD 2938/4885PIK3CB 1706/4885PIK3CG 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.